Singapore-headquartered Everstone Capital, the private equity arm of the Everstone Group, has announced the acquisition of a controlling stake in Softgel Healthcare (SHPL), a specialised niche dosage form-focused manufacturing player catering to the global nutraceutical, pharmaceutical and OTC segments.

The partnership aims to transform SHPL into a scaled, diversified, and globally recognised contract research, development, and manufacturing organisation in India with the support of the strategic resources of Everstone.

Headquartered in Chennai, SHPL is part of the Madras Pharma Group, a leading pharmaceutical contract manufacturing organization in southern India, with eight manufacturing facilities covering all dosage forms. SHPL specialises in the research, development and manufacturing of soft gelatin capsules and probiotics. Its customers span across the Americas, Africa, Asia and India with over 80 per cent of its sales being in exports. It has a state-of-the-art manufacturing facility in Chennai, conforming to globally recognized certifications and registrations such as USFDA, TGA, EU-GMP, Health Canada, among others.